Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and sea

International Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 156-163

  Rosendahl, Alexander ^a   Kristensson, Karin ^a   Carlsson, Mats ^a   Skartved, Niels Jørgen ^a   Riesbeck, Kristian ^a   Søgaard, Morten ^a   Dohlsten, Mikael ^b  

^a Active Biotech Research AB   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL SELECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; EFFECTOR CELL; FEMALE; GENETIC TRANSFECTION; IMMUNOGENICITY; LUNG METASTASIS; LYMPHOCYTE FUNCTION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CANCER VACCINES; DRUG SYNERGISM; ENTEROTOXINS; FEMALE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INTERFERON TYPE II; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033044226     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990331)81:1<156::AID-IJC25>3.0.CO;2-H     Document Type: Article

References (34)

1. ABRAHMSEN, L., DOHLSTEN, M., SEGREN, S., BIORK, P., JONSSON, E. and KALLAND, T., Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J., 14, 2978-2986 (1995).
2. AKBAR, A.N., BORTHWICK, N.J., WICKREMASINGHE, R.G., PANAYOITIDIS, P., PILLING, D., BOFILL, M., KRAJEWSKI, S., REED, J.C. and SALMON, M., Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Europ. J. Immunol., 26, 294-299 (1996).
3. BECKER, J.C., PANCOOK, J.D., GILLIES, S.D., MENDELSOHN, J. and REISFELD, R. A., Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. nat. Acad. Sci. (Wash.), 93, 2702-2707 (1996).
4. BELFRAGE, H., DOHLSTEN, M., HEDLUND, G. and KALLAND, T., Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment. Cancer Immunol. Immunother., 44, 77-82 (1997).
5. CARLSSON, R. and SJÖGREN, H.O., Kinetics of IL-2 and interferon-gamma production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to staphylococcal enterotoxin A. Cell Immunol., 96, 175-183 (1985).
6. CIANCIOLO, G.J., Antiinflammatory proteins associated with human and murine neoplasms. Biochim. biophys. Acta., 865, 69-82 (1986).
7. CIANCIOLO, G.J. and SNYDERMAN, R., Effects of tumor growth on host defenses. Cancer Metastasis Rev., 5, 15-27 (1986).
8. DOHLSTEN, M., BJORKLUND, M., SUNDSTEDT, A., HEDLUND, G., SAMSON, D. and KALLAND, T., Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology, 79, 520-527 (1993).
9. DOHLSTEN, M., HANSSON, J., OHLSSON, L., LITTON, M. and KALLAND, T., Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc. nat. Acad. Sci. (Wash.), 92, 9791-9795 (1995).
10. DOHLSTEN, M., HEDLUND, G., AKERBLOM, E., LANDO, P.A. and KALLAND, T., Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc. nat. Acad. Sci. (Wash.), 88, 9287-9291 (1991).
11. DOHLSTEN, M., LANDO, P.A., HEDLUND, G., TROWSDALE, J. and KALLAND, T., Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology, 71, 96-100 (1990).
12. DUMMER, R., GORE, M.E., HANCOCK, B.W., GUILLOU, P.J., GROBBEN, H.C., BECKER, J.C., OSKAM, R., DIELEMAN, J.P. and BURG, G., A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer, 75, 1038-1044 (1995).
13. + T cells. Science, 271, 1276-1278 (1996).
14. FISCHER, H., DOHLSTEN, M., ANDERSSON, U., HEDLUND, G., ERICSSON, P., HANSSON, J. and SJÖGREN, H.O., Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J. Immunol., 144, 4663-1669 (1990).
15. FORSBERG, G., FORSGREN, M., JAKI, M., NORIN, M., STERKY, C., ENHORNING, A., LARSSON, K., ERICSSON, M. and BJÖRK, P., Identification of framework residues in a secreted recombinant antibody fragment that control production level and localisation in Escherichia coli. J. biol. Chem., 272, 12430-12436 (1997).
16. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R. and GILBOA, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. exp. Med., 172, 1217-1224 (1990).
17. GILLIES, S.D., YOUNG, D., Lo, K.M. and ROBERTS, S., Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug. Chem., 4, 230-235 (1993).
18. GOMEZ, J., MARTINEZ, C., FERNANDEZ, B., GARCIA, A. and REBOLLO, A., Ras activation leads to cell proliferation or apoptotic cell death upon interleukin-2 stimulation or lymphokine deprivation, respectively. Europ. J. Immunol., 27, 1610-1618 (1997).
19. KAGI, D., LEDERMANN, B., BURKI, K., SEILER, P., ODERMATT, B., OLSEN, K.J., PODACK, E.R., ZINKERNAGEL, R.M. and HENGARTNER, H., Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (Lond.). 369, 31-37 (1994).
20. KANG, S.M., BEVERLY, B., TRAN, A.C., BRORSON, K., SCHWARTZ, R.H. and LENARDO, M.J., Transactivation by AP-I is a molecular target of T cell clonal anergy. Science, 257, 1134-1138 (1992).
21. KONO, K., SALAZAR ONFRAY, F., PETERSSON, M., HANSSON, J., MASUCCI, G., WASSERMAN, K., NAKAZAWA, T., ANDERSON, P. and KIESSLING, R., Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Europ. J. Immunol., 26, 1308-1313 (1996).
22. + T cells. Science, 271, 1272-1276 (1996).
23. LITTON, M.J., DOHLSTEN, M., HANSSON, J., ROSENDAHL, A., OHLSSON, L., KALLAND, T., ANDERSSON, J. and ANDERSSON, U., Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Amer. J. Pathol., 150, 1607-1618 (1997).
24. MAREEL, M., DRAGONETTI, C., TAVERNIER, J. and FIERS, W., Tumor-selective cytotoxic effects of murine tumor necrosis factor (TNF) and interferon-gamma (IFN-gamma) in organ culture of B16 melanoma cells and heart tissue. Int. J. Cancer, 42, 470-473 (1988).
25. NEMOTO, T., TAKESHITA, T. ISHII, N., KONDO, M., HIGUCHI, M., SATOMI, S., NAKAMURA, M., MORI, S. and SUGAMURA, K., Differences in the interleukin-2 (IL-2) receptor system in human and mouse: alpha chain is required for formation of the functional mouse IL-2 receptor. Europ. J. Immunol., 25, 3001-3005 (1995).
26. PARDOLL, D.M., Cancer vaccines. Trends Pharmacol. Sci., 14, 202-208 (1993).
27. PODACK, E.R. and KUPFER, A., T-cell effector functions: mechanisms for delivery of cytotoxicity and help. Ann. Rev. Cell Biol., 7, 479-504 (1991).
28. ROSENDAHL, A., HANSSON, J., SUNDSTEDT, A., KALLAND, T. and DOHLSTEN, M., Immune response during tumor therapy with antibody-superantigen fusion proteins. Int. J. Cancer, 68, 109-113 (1996).
29. ROSENDAHL, A., KRISTENSSON, K., HANSSON, J., OHLSSON, L., KALLAND, T. and DOHLSTEN, M., Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth. Int. J. Cancer, 76, 274-283 (1998a).
30. ROSENDAHL, A., KRISTENSSON, K., HANSSON, J., RIESBECK, K., KALLAND, T. and DOHLSTEN, M., Perform and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J. Immunol., 160, 5309-5313 (1998b).
31. SAKURAI, M., IIGO, M., TAMURA, T., OTSU, A., SASAKI, Y., NAKANO, H., NAKAGAWA, K., MINATO, K., OHE, Y. and SAIJO, N., Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma. Cancer Immunol. Immunother., 26, 109-113 (1988).
32. SUNDSTEDT, A., HÖIDEN, I., ROSENDAHL, A., KALLAND, T., VAN ROOIJEN, N. and DOHLSTEN, M., Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J. Immunol., 158, 180-186 (1997).
33. + T cells express perturbed AP-I and NF-kappa B transcription factors. Proc. nat. Acad. Sci. (Wash.), 93, 979-984 (1996).
34. YOUNG, M.R., WRIGHT, M.A., MATTHEWS, J.P., MALIK, I. and PRECHEL, M., Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J. Immunol., 156, 1916-1922 (1996).